Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306253104> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4306253104 abstract "Cannabidiol (CBD) is the most abundant non-psychotropic cannabinoid constituent of Cannabis sativa. CBD is potentially therapeutic for the eye through antioxidant, anti-inflammatory, and neuroprotective effects. However, the effect of CBD on intraocular pressure (IOP)- the major risk factor for glaucoma- is controversial and large variability exists in the literature. IOP is regulated through aqueous humor (AH) dynamics in trabecular meshwork (TM) tissues. Measurement of CBD in AH and correlation with effects on IOP would clarify what concentrations mediate changes to IOP. Therefore, the overall goal of this dissertation is to measure CBD in ocular tissues and correlate concentrations with ocular pharmacologic effects. Effects of CBD on AH outflow were measured in porcine anterior segment explants. Effects of CBD on TM contractility and Rho/ROCK signaling were assessed in vitro. Porcine AH CBD concentrations were measured following ocular topical application ex vivo. A cyclodextrin solution, cyclodextrin solution containing gellan gum (GG) which forms a hydrogel in situ, and a semifluorinated alkane (SFA) were used to apply CBD topically. Murine AH and serum were measured by LC-MS/MS, and porcine AH and cornea concentrations were measured by HPLC. IOP was assessed following intraperitoneal and topical administration in vivo. Corneal analgesia of topical CBD was assessed using an eye wiping test. CBD increased AH outflow ex vivo, decreased TM cell contractility and inhibited TM Rho/ROCK signaling in vitro. Intraperitoneal administration of CBD reached an AH Cmax of 71.55 ng/mL and decreased IOP lasting up to 4 hours. AH concentration of CBD time dependently increased following topical application ex vivo when applied in cyclodextrin vehicles but was localized to the cornea when applied in SFA. Topical CBD lowered IOP when applied in cyclodextrin containing vehicles and reduced corneal pain when applied in an SFA vehicle. Addition of GG increased AH concentrations (Cmax 1864 ng/mL) and extended IOP reduction (from 5 to 8 hours) relative to cyclodextrin-only formulations. We have determined that low micromolar CBD concentrations alter AH outflow and IOP, and vehicle chosen can localize CBD delivery. The results highlight the importance of not only vehicle but also tissue concentrations for CBD mediated pharmacologic effects." @default.
- W4306253104 created "2022-10-15" @default.
- W4306253104 creator A5063236469 @default.
- W4306253104 date "2022-10-14" @default.
- W4306253104 modified "2023-10-01" @default.
- W4306253104 title "Application of cannabidol to ocular pharmacokinetics and pharmacodynamics." @default.
- W4306253104 doi "https://doi.org/10.18297/etd/3952" @default.
- W4306253104 hasPublicationYear "2022" @default.
- W4306253104 type Work @default.
- W4306253104 citedByCount "0" @default.
- W4306253104 crossrefType "dissertation" @default.
- W4306253104 hasAuthorship W4306253104A5063236469 @default.
- W4306253104 hasBestOaLocation W43062531041 @default.
- W4306253104 hasConcept C112705442 @default.
- W4306253104 hasConcept C118487528 @default.
- W4306253104 hasConcept C118552586 @default.
- W4306253104 hasConcept C150903083 @default.
- W4306253104 hasConcept C170493617 @default.
- W4306253104 hasConcept C185592680 @default.
- W4306253104 hasConcept C202751555 @default.
- W4306253104 hasConcept C207001950 @default.
- W4306253104 hasConcept C22979827 @default.
- W4306253104 hasConcept C26291073 @default.
- W4306253104 hasConcept C2776882836 @default.
- W4306253104 hasConcept C2776895053 @default.
- W4306253104 hasConcept C2777056318 @default.
- W4306253104 hasConcept C2780871563 @default.
- W4306253104 hasConcept C2781092963 @default.
- W4306253104 hasConcept C2781121420 @default.
- W4306253104 hasConcept C55493867 @default.
- W4306253104 hasConcept C71924100 @default.
- W4306253104 hasConcept C86803240 @default.
- W4306253104 hasConcept C98274493 @default.
- W4306253104 hasConceptScore W4306253104C112705442 @default.
- W4306253104 hasConceptScore W4306253104C118487528 @default.
- W4306253104 hasConceptScore W4306253104C118552586 @default.
- W4306253104 hasConceptScore W4306253104C150903083 @default.
- W4306253104 hasConceptScore W4306253104C170493617 @default.
- W4306253104 hasConceptScore W4306253104C185592680 @default.
- W4306253104 hasConceptScore W4306253104C202751555 @default.
- W4306253104 hasConceptScore W4306253104C207001950 @default.
- W4306253104 hasConceptScore W4306253104C22979827 @default.
- W4306253104 hasConceptScore W4306253104C26291073 @default.
- W4306253104 hasConceptScore W4306253104C2776882836 @default.
- W4306253104 hasConceptScore W4306253104C2776895053 @default.
- W4306253104 hasConceptScore W4306253104C2777056318 @default.
- W4306253104 hasConceptScore W4306253104C2780871563 @default.
- W4306253104 hasConceptScore W4306253104C2781092963 @default.
- W4306253104 hasConceptScore W4306253104C2781121420 @default.
- W4306253104 hasConceptScore W4306253104C55493867 @default.
- W4306253104 hasConceptScore W4306253104C71924100 @default.
- W4306253104 hasConceptScore W4306253104C86803240 @default.
- W4306253104 hasConceptScore W4306253104C98274493 @default.
- W4306253104 hasLocation W43062531041 @default.
- W4306253104 hasOpenAccess W4306253104 @default.
- W4306253104 hasPrimaryLocation W43062531041 @default.
- W4306253104 hasRelatedWork W1943820892 @default.
- W4306253104 hasRelatedWork W202343169 @default.
- W4306253104 hasRelatedWork W2057097799 @default.
- W4306253104 hasRelatedWork W2075468019 @default.
- W4306253104 hasRelatedWork W2122374784 @default.
- W4306253104 hasRelatedWork W2144430913 @default.
- W4306253104 hasRelatedWork W2464608421 @default.
- W4306253104 hasRelatedWork W3000071749 @default.
- W4306253104 hasRelatedWork W3028970082 @default.
- W4306253104 hasRelatedWork W4283836187 @default.
- W4306253104 isParatext "false" @default.
- W4306253104 isRetracted "false" @default.
- W4306253104 workType "dissertation" @default.